Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ816MR)

This product GTTS-WQ816MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ816MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5275MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ5625MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ15719MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ4686MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ13410MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ7599MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ6287MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ8705MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW